Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 51

Sort by

Sort Order Select

Journal Articles

Clinico-Pathological Characteristics, Treatments and Outcomes of Patients with Dendritic Cell Sarcoma (DS)

Preetesh Jain, MBBS,MDDM,PhD, Keyur P. Patel, MD PhD, Andrew Futreal, PhD, Curtis Gumbs, Shimin Hu, PhD MD, Carlos Bueso Ramos, MD, Michael Wang, MD, Jorge Romaguera, Luis E. Fayad, MD, Robert Z. Orlowski, PhD, MD, Jeffrey Medeiros, Nathan Fowler, MD

Blood (2015) 126 (23): 2700.

https://doi.org/10.1182/blood.V126.23.2700.2700

Published: 2015

Journal Articles

A Phase I Trial of Alisertib Plus Romidepsin for Relapsed/Refractory Aggressive B- and T-Cell Lymphomas

Michelle A. Fanale, MD, Fredrick B. Hagemeister, MD, Luis Fayad, MD, Yasuhiro Oki, MD, Nathan Fowler, MD, Jorge Romaguera, MD, Nina Shah, Hubert Chuang, MD, Lei Feng, MS, Sandra B Horowitz, PharmD, Emily Wesson, APN, Toni Y Hutto, BS, Tariq Muzzafar, MD, Felipe Samaniego, MD, R Eric Davis, MD

Blood (2014) 124 (21): 1744.

https://doi.org/10.1182/blood.V124.21.1744.1744

Published: 2014

Journal Articles

Development of Non-Hodgkin’s Lymphoma As Second Primary Cancer in Hepatitis C Virus-Infected Patients with a Different Primary Malignancy – a Case Series

Parag Mahale, MBBS, MPH, Jorge Romaguera, MD, Francesco Turturro, MD, Nathan Fowler, MD, Harrys A. Torres, MD FACP

Blood (2014) 124 (21): 5414.

https://doi.org/10.1182/blood.V124.21.5414.5414

Published: 2014

Journal Articles

The Effect of Different Rituximab-Containing Chemotherapy Strategies on Hepatitis C Viremia

Parag Mahale, MBBS, MPH, Francesco Turturro, MD, Jorge Romaguera, MD, Nathan Fowler, MD, Harrys A. Torres, MD FACP

Blood (2014) 124 (21): 4448.

https://doi.org/10.1182/blood.V124.21.4448.4448

Published: 2014

Journal Articles

Long Term Follow-Up Of De Novo Or Minimally Treated Burkitt Lymphoma/Leukemia (BL/B-ALL) After Frontline Therapy Per The Hyper-CVAD Regimen With Or Without Rituximab: 20-Year Cumulative Experience

Preetesh Jain, MD, DM, PhD, Hagop M Kantarjian, MD, Jorge E. Cortes, MD, Elias J. Jabbour, MD, Stefan H. Faderl, MD, William G. Wierda, MD, PhD, Guillermo Garcia-Manero, MD, Alessandra Ferrajoli, MD, Srdan Verstovsek, MD, PhD, Jan A. Burger, MD, PhD, Luis Fayad, MD, Jorge Romaguera, MD, Rebecca Garris, BSc, Farhad Ravandi, MD, Susan O'Brien, MD, Deborah Thomas, MD

Blood (2013) 122 (21): 3917.

https://doi.org/10.1182/blood.V122.21.3917.3917

Published: 2013

Journal Articles

TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas

Jinsheng Weng, Seema Rawal, Fuliang Chu, Hyun Jun Park, Rakesh Sharma, David A. Delgado, Luis Fayad, Michelle Fanale, Jorge Romaguera, Amber Luong, Larry W. Kwak, Sattva S. Neelapu

Blood (2012) 120 (8): 1613–1623.

https://doi.org/10.1182/blood-2011-09-382838

Published: 2012

Includes: Supplemental data

Journal Articles

Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma

Blood (2012) 119 (18): 4123–4128.

https://doi.org/10.1182/blood-2012-01-405456

Published: 2012

Includes: Supplemental data

Journal Articles

Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activities

Hyun Joo Jung, Zheng Chen, Michael Wang, Luis Fayad, Jorge Romaguera, Larry W. Kwak, Nami McCarty

Blood (2012) 119 (11): 2568–2578.

https://doi.org/10.1182/blood-2011-09-377598

Published: 2012

Includes: Supplemental data

Journal Articles

Experience with obatoclax mesylate (GX15-070), a small molecule pan–Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma

Yasuhiro Oki, Amanda Copeland, Fredrick Hagemeister, Luis E. Fayad, Michelle Fanale, Jorge Romaguera, Anas Younes

Blood (2012) 119 (9): 2171–2172.

https://doi.org/10.1182/blood-2011-11-391037

Published: 2012

Journal Articles

Long-Term Outcome for De Novo or Minimally Treated Burkitt-Type Lymphoma/Leukemia (BL/B-ALL) After Therapy with Hyper-CVAD and Rituximab

Deborah A. Thomas, MD, Susan O'Brien, MD, Jorge E. Cortes, MD, Stefan Faderl, MD, William G. Wierda, MD, PhD, Guillermo Garcia-Manero, MD, Elias Jabbour, MD, Alessandra Ferrajoli, MD, Srdan Verstovsek, MD, PhD, Jan A. Burger, MD, PhD, Rebecca Garris, BA, Jorge Romaguera, MD, Fredrick Hagemeister, MD, Hagop Kantarjian, MD

Blood (2010) 116 (21): 1781.

https://doi.org/10.1182/blood.V116.21.1781.1781

Published: 2010

Journal Articles

Outcomes of Nodular Lymphocyte Predominant Hodgkin's Lymphoma (NLPHL) Patients Treated with R-CHOP.

Michelle A. Fanale, MD, Chao-Ming Lai, APN, Peter McLaughlin, MD, Jorge Romaguera, MD, Luis Fayad, MD, Fredrick Hagemeister, MD, Felipe Samaniego, MD, MPH, Maria Alma Rodriguez, MD, Sattva S. Neelapu, Jatin J Shah, MD, Larry Kwak, Wenli Dong, Valerie Reed, MD, Bouthaina S. Dabaja, MD, Uday Popat, MD, Anas Younes, MD

Blood (2010) 116 (21): 2812.

https://doi.org/10.1182/blood.V116.21.2812.2812

Published: 2010

Journal Articles

Long-Term Outcome for De Novo Lymphoblastic Lymphoma (LL) After Frontline Therapy with Hyper-CVAD Regimen and Variants.

Deborah A. Thomas, MD, Stefan Faderl, MD, Susan O'Brien, MD, William G. Wierda, MD, PhD, Guillermo Garcia-Manero, MD, Srdan Verstovsek, MD, PhD, Marina Konopleva, MD, PhD, Tapan Kadia, MD, Steven M. Kornblau, MD, Luis Fayad, MD, Jorge Romaguera, MD, Jorge E. Cortes, MD, Hagop Kantarjian, MD

Blood (2010) 116 (21): 2831.

https://doi.org/10.1182/blood.V116.21.2831.2831

Published: 2010

Journal Articles

Final Report of a Phase-II Study of Rituximab Plus ABVD for Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma.: Results of Long Follow up and Comparison to Institutional Historical Data.

Amanda R Copeland, MS, Yumei Cao, MD, Michelle Fanale, M.D., Luis Fayad, MD, Peter McLaughlin, Barbara Pro, MD, Fredrick Hagemeister, Jorge Romaguera, MD, Felipe Samaniego, MD, Alma Rodriguez, MD, Anas Younes, MD

Blood (2009) 114 (22): 1680.

https://doi.org/10.1182/blood.V114.22.1680.1680

Published: 2009

Journal Articles

Safety and Tolerability of Conatumumab in Combination with Bortezomib or Vorinostat in Patients with Relapsed or Refractory Lymphoma.

Anas Younes, MD, Mark Kirschbaum, MD, Lubomir Sokol, MD, PhD, Lorrin Yee, Jorge Romaguera, MD, Lovely Goyal, Cheng-Pang Hsu, Yuying Hwang, Kevin Gorski, Susan Wong, Darrin M. Beaupre, MD, PhD

Blood (2009) 114 (22): 1708.

https://doi.org/10.1182/blood.V114.22.1708.1708

Published: 2009

Journal Articles

Phase I Multi-Dose Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous (IV) Infusion Every 3 Weeks to Patients with Relapsed/ Refractory B-Cell Non-Hodgkin's Lymphoma (NHL).

Anas Younes, MD, Leo Gordon, MD, Stella Kim, MD, Jorge Romaguera, MD, Amanda R Copeland, MS, Silvana de Castro Farial, MD, Larry Kwak, MD, PHD, Luis Fayad, MD, Frederick Hagemeister, MD, Michelle Fanale, M.D., John Lambert, PhD, Teresa Bagulho, MD, Rodica Morariu-Zamfir, MD

Blood (2009) 114 (22): 585.

https://doi.org/10.1182/blood.V114.22.585.585

Published: 2009

Journal Articles

Clinical and Biologic Activity of the Heat Shock Protein-90 (HSP-90) Inhibitor 17-AAG in Patients with Relapsed Lymphoma.

Anas Younes, MD, Amanda R Copeland, MS, Jorge Romaguera, MD, Luis Fayad, MD, Michelle Fanale, M.D., Silvana de Castro Faria, MD, PhD, L. Jeffrey Medeiros, MD, Ph.D, S. Percy Ivy, MD

Blood (2009) 114 (22): 3744.

https://doi.org/10.1182/blood.V114.22.3744.3744

Published: 2009

Journal Articles

Randomized Clinical Trial of Rasburicase Administered as a Standard Fixed Five Days Dosing Vs a Single Dose Followed by as Needed Dosing in Adult Patients with Hematologic Malignancies at Risk for Developing Tumor Lysis Syndrome.

Saroj Vadhan-Raj, MD, Luis Fayad, MD, Michelle Fanale, M.D., Barbara Pro, Alma Rodriguez, Frederick Hagemeister, Kandice Ames, RN, Carlos E. Bueso-Ramos, MD, Xiao Zhou, MD, PHD, Peter McLaughlin, Nathan Fowler, Jatin Shah, MD, Felipe Samaniego, MD, Anas Younes, MD, Larry Kwak, MD, PHD, Jorge Romaguera, MD

Blood (2009) 114 (22): 105.

https://doi.org/10.1182/blood.V114.22.105.105

Published: 2009

Journal Articles

A Phase I/II Study of Lenalidomide in Combination with Rituximab in Relapsed/Refractory Mantle Cell Lymphoma.

Luhua Wang, MD, Luis Fayad, MD, Fredrick B. Hagemeister, MD, Sattva Neelapu, MD, Felipe Samaniego, MD, Peter McLaughlin, MD, Barry Samuels, MD, Qing Yi, MD, PhD, Barbara Pro, MD, Michelle Fanale, M.D., Jatin Shah, MD, Anas Younes, MD, Neda Bell, Robert Knight, MD, Jerome B. Zeldis, MD, PhD, Fernando Cabanillas, MD, Larry Kwak, MD, PHD, Jorge Romaguera, MD

Blood (2009) 114 (22): 2719.

https://doi.org/10.1182/blood.V114.22.2719.2719

Published: 2009

Journal Articles

Phase I Trial of Bortezomib in Combination with Rituximab-HyperCVAD/Methotrexate and Cytarabine for Untreated Mantle Cell Lymphoma

Jorge Romaguera, MD, Luis Fayad, Peter McLaughlin, MD, Barbara Pro, MD, Maria Alma Rodriguez, MD, Michael Wang, MD, Pamela Weaver, RN, Kimberly Hartig, Larry Kwak, MD, PhD, Tatyana Feldman, MD, Judy Smith, RN, Peggy Ford, RN, Stuart Goldberg, MD, Andrew Pecora, MD, Andre Goy, MD

Blood (2008) 112 (11): 3051.

https://doi.org/10.1182/blood.V112.11.3051.3051

Published: 2008

Journal Articles

Lenalidomide and Rituximab Are a Promising Combination in Vitro, in Vivo Preclinically and in a Phase I/II Clinical Trial in Relapsed/Refractory Mantle Cell Lymphoma

Michael Wang, MD, Liang Zhang, PhD, Luis Fayad, MD, Fredrick Hagemeister, MD, Sattva Neelapu, MD, Felipe Samaniego, M.D., Barbara Pro, MD, Anas Younes, MD, Scott Miller, Robert D. Knight, MD, Jerome B. Zeldis, MD, Qing Yi, MD, PhD, Jorge Romaguera, MD

Blood (2008) 112 (11): 3058.

https://doi.org/10.1182/blood.V112.11.3058.3058

Published: 2008

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Clinico-Pathological Characteristics, Treatments and Outcomes of Patients with Dendritic Cell Sarcoma (DS)

A Phase I Trial of Alisertib Plus Romidepsin for Relapsed/Refractory Aggressive B- and T-Cell Lymphomas

Development of Non-Hodgkin’s Lymphoma As Second Primary Cancer in Hepatitis C Virus-Infected Patients with a Different Primary Malignancy – a Case Series

The Effect of Different Rituximab-Containing Chemotherapy Strategies on Hepatitis C Viremia

Long Term Follow-Up Of De Novo Or Minimally Treated Burkitt Lymphoma/Leukemia (BL/B-ALL) After Frontline Therapy Per The Hyper-CVAD Regimen With Or Without Rituximab: 20-Year Cumulative Experience

TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas

Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma

Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activities

Experience with obatoclax mesylate (GX15-070), a small molecule pan–Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma

Long-Term Outcome for De Novo or Minimally Treated Burkitt-Type Lymphoma/Leukemia (BL/B-ALL) After Therapy with Hyper-CVAD and Rituximab

Outcomes of Nodular Lymphocyte Predominant Hodgkin's Lymphoma (NLPHL) Patients Treated with R-CHOP.

Long-Term Outcome for De Novo Lymphoblastic Lymphoma (LL) After Frontline Therapy with Hyper-CVAD Regimen and Variants.

Final Report of a Phase-II Study of Rituximab Plus ABVD for Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma.: Results of Long Follow up and Comparison to Institutional Historical Data.

Safety and Tolerability of Conatumumab in Combination with Bortezomib or Vorinostat in Patients with Relapsed or Refractory Lymphoma.

Phase I Multi-Dose Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous (IV) Infusion Every 3 Weeks to Patients with Relapsed/ Refractory B-Cell Non-Hodgkin's Lymphoma (NHL).

Clinical and Biologic Activity of the Heat Shock Protein-90 (HSP-90) Inhibitor 17-AAG in Patients with Relapsed Lymphoma.

Randomized Clinical Trial of Rasburicase Administered as a Standard Fixed Five Days Dosing Vs a Single Dose Followed by as Needed Dosing in Adult Patients with Hematologic Malignancies at Risk for Developing Tumor Lysis Syndrome.

A Phase I/II Study of Lenalidomide in Combination with Rituximab in Relapsed/Refractory Mantle Cell Lymphoma.

Phase I Trial of Bortezomib in Combination with Rituximab-HyperCVAD/Methotrexate and Cytarabine for Untreated Mantle Cell Lymphoma

Lenalidomide and Rituximab Are a Promising Combination in Vitro, in Vivo Preclinically and in a Phase I/II Clinical Trial in Relapsed/Refractory Mantle Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only